The Fred Hutchinson/University of Washington Cancer Consortium (Consortium), formed in 2002, is a partnership of: Fred Hutchinson Cancer Research Center, an NCI-designated Comprehensive Cancer Center since 1976 and a CCSG grant recipient since 1973;the University of Washington;and Children's Hospital and Regional Medical Center. The Consortium brings together more than 400 faculty with research interests in basic, clinical and public health sciences related to cancer, with total NCI funding of $73 million (direct costs). The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration between the three institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. The Consortium faculty are organized into 13 productive research programs with emphasis in the Public Health (Biostatistics, Epidemiology, Cancer Prevention), Clinical (Transplantation Biology and Clinical Transplantation), and Fundamental sciences (Basic Sciences, Stem/Progenitor Cell Biology, Genome Instability &Mutagenesis), as well as programs that are highly cross-disciplinary (Women's Cancer;Prostate Cancer;Gl Cancer Etiology, Prevention, &Early Detection;Cancer Imaging;and Immunology &Vaccine Development). During the next grant period the Consortium will seek to: (1) Strengthen its clinical research programs and infrastructure to permit more rapid development of diagnostics and therapeutics;(2) Strengthen its presence in genetic/genomics;(3) Strengthen its presence in computational biology;(4) Continue its commitment to early cancer detection, including protein biomarker discovery and molecular diagnostics;(5) Build on leadership in research on infectious diseases and virology and develop a program focusing on infectious agents and cancer;(6) Continue to recruit promising laboratory scientists in broad areas of basic biology;and (7) Continue to encourage and support a focus on aging for relevant programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-37S4
Application #
8323033
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-01-01
Project End
2013-12-31
Budget Start
2011-09-01
Budget End
2011-12-31
Support Year
37
Fiscal Year
2011
Total Cost
$75,000
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Mora-Pinzon, Maria C; Trentham-Dietz, Amy; Gangnon, Ronald E et al. (2018) Urinary Magnesium and Other Elements in Relation to Mammographic Breast Density, a Measure of Breast Cancer Risk. Nutr Cancer 70:441-446
Shirts, Brian H; Konnick, Eric Q; Upham, Sarah et al. (2018) Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 103:19-29
Du, Jing; Flynn, Ryan; Paz, Katelyn et al. (2018) Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood 131:1743-1754
Suzuki, Aussie; Gupta, Amitabha; Long, Sarah K et al. (2018) A Kinesin-5, Cin8, Recruits Protein Phosphatase 1 to Kinetochores and Regulates Chromosome Segregation. Curr Biol 28:2697-2704.e3
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis. J Cell Sci 131:
Kuzma, Jessica N; Hagman, Derek K; Cromer, Gail et al. (2018) Intra-individual variation in markers of intestinal permeability and adipose tissue inflammation in healthy normal weight to obese adults. Cancer Epidemiol Biomarkers Prev :
Adrianse, Robin L; Smith, Kaleb; Gatbonton-Schwager, Tonibelle et al. (2018) Perturbed maintenance of transcriptional repression on the inactive X-chromosome in the mouse brain after Xist deletion. Epigenetics Chromatin 11:50
Walter, Roland B; Othus, Megan; Orlowski, Kaysey F et al. (2018) Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm. Haematologica 103:e106-e109
Thornblade, Lucas W; Mulligan, Michael S; Odem-Davis, Katherine et al. (2018) Challenges in Predicting Recurrence After Resection of Node-Negative Non-Small Cell Lung Cancer. Ann Thorac Surg 106:1460-1467
Poston, Jacqueline N; Fromm, Jonathan R; Rasmussen, Heather A et al. (2018) A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. Br J Haematol :

Showing the most recent 10 out of 1267 publications